367 related articles for article (PubMed ID: 38203175)
21. Role of Farnesoid X Receptor in the Pathogenesis of Respiratory Diseases.
Wu JN; Chen JR; Chen JL
Can Respir J; 2020; 2020():9137251. PubMed ID: 33294085
[TBL] [Abstract][Full Text] [Related]
22. Recent Advances in the Digestive, Metabolic and Therapeutic Effects of Farnesoid X Receptor and Fibroblast Growth Factor 19: From Cholesterol to Bile Acid Signaling.
Di Ciaula A; Bonfrate L; Baj J; Khalil M; Garruti G; Stellaard F; Wang HH; Wang DQ; Portincasa P
Nutrients; 2022 Nov; 14(23):. PubMed ID: 36500979
[TBL] [Abstract][Full Text] [Related]
23. Role of bile acids and bile acid receptors in metabolic regulation.
Lefebvre P; Cariou B; Lien F; Kuipers F; Staels B
Physiol Rev; 2009 Jan; 89(1):147-91. PubMed ID: 19126757
[TBL] [Abstract][Full Text] [Related]
24. Activation of the bile acid receptors TGR5 and FXR in the spinal dorsal horn alleviates neuropathic pain.
Wu Y; Qiu Y; Su M; Wang L; Gong Q; Wei X
CNS Neurosci Ther; 2023 Jul; 29(7):1981-1998. PubMed ID: 36880297
[TBL] [Abstract][Full Text] [Related]
25. Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders.
Fiorucci S; Mencarelli A; Palladino G; Cipriani S
Trends Pharmacol Sci; 2009 Nov; 30(11):570-80. PubMed ID: 19758712
[TBL] [Abstract][Full Text] [Related]
26. Bile acids are nutrient signaling hormones.
Zhou H; Hylemon PB
Steroids; 2014 Aug; 86():62-8. PubMed ID: 24819989
[TBL] [Abstract][Full Text] [Related]
27. Phosphorylation of hepatic farnesoid X receptor by FGF19 signaling-activated Src maintains cholesterol levels and protects from atherosclerosis.
Byun S; Jung H; Chen J; Kim YC; Kim DH; Kong B; Guo G; Kemper B; Kemper JK
J Biol Chem; 2019 May; 294(22):8732-8744. PubMed ID: 30996006
[TBL] [Abstract][Full Text] [Related]
28. Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities.
Radun R; Trauner M
Semin Liver Dis; 2021 Nov; 41(4):461-475. PubMed ID: 34289507
[TBL] [Abstract][Full Text] [Related]
29. Farnesoid X receptor: A "homeostat" for hepatic nutrient metabolism.
Massafra V; van Mil SWC
Biochim Biophys Acta Mol Basis Dis; 2018 Jan; 1864(1):45-59. PubMed ID: 28986309
[TBL] [Abstract][Full Text] [Related]
30. Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation.
Degirolamo C; Modica S; Vacca M; Di Tullio G; Morgano A; D'Orazio A; Kannisto K; Parini P; Moschetta A
Hepatology; 2015 Jan; 61(1):161-70. PubMed ID: 24954587
[TBL] [Abstract][Full Text] [Related]
31. Development of bile acid activated receptors hybrid molecules for the treatment of inflammatory and metabolic disorders.
Fiorucci S; Sepe V; Biagioli M; Fiorillo B; Rapacciuolo P; Distrutti E; Zampella A
Biochem Pharmacol; 2023 Oct; 216():115776. PubMed ID: 37659739
[TBL] [Abstract][Full Text] [Related]
32. Norcholic Acid Promotes Tumor Progression and Immune Escape by Regulating Farnesoid X Receptor in Hepatocellular Carcinoma.
Gong Y; Li K; Qin Y; Zeng K; Liu J; Huang S; Chen Y; Yu H; Liu W; Ye L; Yang Y
Front Oncol; 2021; 11():711448. PubMed ID: 34888230
[TBL] [Abstract][Full Text] [Related]
33. Intestinal Farnesoid X Receptor and Takeda G Protein Couple Receptor 5 Signaling in Metabolic Regulation.
Chiang JY; Pathak P; Liu H; Donepudi A; Ferrell J; Boehme S
Dig Dis; 2017; 35(3):241-245. PubMed ID: 28249273
[TBL] [Abstract][Full Text] [Related]
34. Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism.
Pathak P; Xie C; Nichols RG; Ferrell JM; Boehme S; Krausz KW; Patterson AD; Gonzalez FJ; Chiang JYL
Hepatology; 2018 Oct; 68(4):1574-1588. PubMed ID: 29486523
[TBL] [Abstract][Full Text] [Related]
35. Bile Acids and FXR: Novel Targets for Liver Diseases.
Stofan M; Guo GL
Front Med (Lausanne); 2020; 7():544. PubMed ID: 33015098
[TBL] [Abstract][Full Text] [Related]
36. Inactivation of Adenomatous Polyposis Coli Reduces Bile Acid/Farnesoid X Receptor Expression through Fxr gene CpG Methylation in Mouse Colon Tumors and Human Colon Cancer Cells.
Selmin OI; Fang C; Lyon AM; Doetschman TC; Thompson PA; Martinez JD; Smith JW; Lance PM; Romagnolo DF
J Nutr; 2016 Feb; 146(2):236-42. PubMed ID: 26609171
[TBL] [Abstract][Full Text] [Related]
37. Disordered farnesoid X receptor signaling is associated with liver carcinogenesis in Abcb11-deficient mice.
Wang L; Luo Q; Zeng S; Lou Y; Li X; Hu M; Lu L; Liu Z
J Pathol; 2021 Dec; 255(4):412-424. PubMed ID: 34410012
[TBL] [Abstract][Full Text] [Related]
38. Long-term Administration of Nuclear Bile Acid Receptor FXR Agonist Prevents Spontaneous Hepatocarcinogenesis in Abcb4
Cariello M; Peres C; Zerlotin R; Porru E; Sabbà C; Roda A; Moschetta A
Sci Rep; 2017 Sep; 7(1):11203. PubMed ID: 28894223
[TBL] [Abstract][Full Text] [Related]
39. Cholesterol 7α-hydroxylase protects the liver from inflammation and fibrosis by maintaining cholesterol homeostasis.
Liu H; Pathak P; Boehme S; Chiang JL
J Lipid Res; 2016 Oct; 57(10):1831-1844. PubMed ID: 27534992
[TBL] [Abstract][Full Text] [Related]
40. Farnesoid-X receptor as a therapeutic target for inflammatory bowel disease and colorectal cancer.
Zhou M; Wang D; Li X; Cao Y; Yi C; Wiredu Ocansey DK; Zhou Y; Mao F
Front Pharmacol; 2022; 13():1016836. PubMed ID: 36278234
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
